Health Canada recently licensed Octaplas, which can now be considered as an alternative to standard fresh frozen plasma (FFP) for certain indications. Since, on average, 200,000 units of FFP are transfused annually in Canada, the widespread implementation of Octaplas may have significant public health and economic implications. This study investigates the cost-effectiveness position of Octaplas against standard FFP and its budgetary impact to the health care system.

Contents

• Reviewers
• EXECUTIVE SUMMARY
  • The Issue
  • Objectives
  • Methods
  • Results
  • Budget Impact Analysis
  • Conclusions
• 1. INTRODUCTION
  • 1.1 Background
  • 1.2 Technology Overview
  • 1.3 Current Fresh Frozen Plasma Utilization in Canada
  • 1.4 Adverse Reactions Associated with Frozen Plasma Transfusions
• 2. THE ISSUE
• 3. RESEARCH QUESTIONS
• 4. METHODS
  • 4.1 Literature Search
  • 4.2 Selection Criteria
  • 4.3 Data Extraction Method
  • 4.4 Results of Literature Search
• 5. REVIEW OF ECONOMIC STUDIES
• 6. ECONOMIC EVALUATION
  • 6.1 Methods
  • 6.2 Base-Case Results
  • 6.3 Sensitivity Analysis
• 7. BUDGET IMPACT AND BENEFIT ANALYSIS
  • 7.1 Incremental Cost from Switching from Fresh Frozen Plasma to Octaplas
  • 7.2 Potential Savings from Switching to Octaplas
  • 7.3 Net Gain or Loss from Switching to Octaplas
• 8. DISCUSSION
• 9. CONCLUSION
• REFERENCES
• ABBREVIATIONS
• APPENDICES
  • APPENDIX 1 Literature Search Strategy
  • APPENDIX 2 Plasma Prices
  • APPENDIX 3 Annual Plasma Utilization

Authorship: As lead author, Stephen Membe led the project protocol development, supervised the literature review, wrote the initial draft, revised the report, and prepared the final version of certain sections of the report for publication.

Doug Coyle developed the economic model, conducted the economic analysis and prepared the final version of section 6 of the report for publication.

Karen Cimon worked with Stephen Membe to evaluate the articles’ relevance, assess their quality, extract data, and organize the report.

Alan Tinmouth provided clinical expertise and contributed to the draft document and its subsequent revisions.

Sarah Normandin was responsible for the design and execution of the literature search strategies, writing the section and associated appendix on literature searching, and verifying and formatting the bibliographic references.

Don Husereau reviewed the report and contributed to the discussion and background.

CADTH is funded by Canadian federal, provincial, and territorial governments.

Suggested citation:

Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S. Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Technology report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011.

CADTH Disclaimer

This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared.

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders and policy-makers make well-informed decisions and thereby improve the quality of health care services.

The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.

Production of this report is made possible through a financial contribution from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and Yukon.

This document may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites.

Conflicts of Interests: No conflicts of interest were declared by the reviewers and authors.

This report is a review of existing literature, studies, materials, other information, and documentation (collectively the “source documentation”) that are available to CADTH. The accuracy of the contents of the source documentation on which this report is based is not warranted, assured, or represented in any way by CADTH, and CADTH does not assume responsibility for the quality, propriety, inaccuracies, or reasonableness of any statements, information, or conclusions contained in the source documentation.